OA12756A - 3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors. - Google Patents

3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors. Download PDF

Info

Publication number
OA12756A
OA12756A OA1200400190A OA1200400190A OA12756A OA 12756 A OA12756 A OA 12756A OA 1200400190 A OA1200400190 A OA 1200400190A OA 1200400190 A OA1200400190 A OA 1200400190A OA 12756 A OA12756 A OA 12756A
Authority
OA
OAPI
Prior art keywords
préparation
hydrogen
compound according
nmr
400mhz
Prior art date
Application number
OA1200400190A
Other languages
English (en)
Inventor
Charlotte Moira Norfo Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of OA12756A publication Critical patent/OA12756A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200400190A 2002-01-22 2003-01-10 3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors. OA12756A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids

Publications (1)

Publication Number Publication Date
OA12756A true OA12756A (en) 2006-07-03

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400190A OA12756A (en) 2002-01-22 2003-01-10 3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors.

Country Status (24)

Country Link
EP (1) EP1467731A1 (is)
JP (1) JP2005520811A (is)
KR (1) KR20040077775A (is)
CN (1) CN1620291A (is)
AP (1) AP2004003084A0 (is)
AR (1) AR038197A1 (is)
BR (1) BR0307016A (is)
CA (1) CA2472238A1 (is)
EA (1) EA200400716A1 (is)
EC (1) ECSP045200A (is)
HR (1) HRP20040659A2 (is)
IL (1) IL162677A0 (is)
IS (1) IS7310A (is)
MA (1) MA27167A1 (is)
MX (1) MXPA04006573A (is)
NO (1) NO20043457L (is)
OA (1) OA12756A (is)
PA (1) PA8563501A1 (is)
PE (1) PE20030929A1 (is)
PL (1) PL371487A1 (is)
TN (1) TNSN04121A1 (is)
TW (1) TW200302094A (is)
UY (1) UY27615A1 (is)
WO (1) WO2003061652A1 (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
WO2006113247A1 (en) * 2005-04-18 2006-10-26 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
TW201033184A (en) * 2008-12-05 2010-09-16 Mochida Pharm Co Ltd Morpholinone compounds as factor IXa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
CN105801489B (zh) * 2010-03-18 2019-12-10 第一三共株式会社 环烷基取代的咪唑衍生物
JP5778133B2 (ja) * 2010-03-18 2015-09-16 第一三共株式会社 シクロプロパンカルボン酸誘導体
AU2014280329A1 (en) 2013-06-10 2016-01-07 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
KR20180123038A (ko) 2016-03-29 2018-11-14 다이이찌 산쿄 가부시키가이샤 염증성 장질환 치료제
JP7158393B2 (ja) 2017-09-14 2022-10-21 第一三共株式会社 環状構造を有する化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
WO2002014285A1 (en) * 2000-08-17 2002-02-21 Pfizer Limited Substituted imidazoles as tafia inhibitors

Also Published As

Publication number Publication date
IL162677A0 (en) 2005-11-20
EA200400716A1 (ru) 2004-12-30
PA8563501A1 (es) 2004-08-31
PE20030929A1 (es) 2003-11-05
NO20043457L (no) 2004-08-19
JP2005520811A (ja) 2005-07-14
MA27167A1 (fr) 2005-01-03
MXPA04006573A (es) 2004-10-04
AP2004003084A0 (en) 2004-09-30
ECSP045200A (es) 2004-08-27
KR20040077775A (ko) 2004-09-06
WO2003061652A1 (en) 2003-07-31
BR0307016A (pt) 2004-11-03
AR038197A1 (es) 2005-01-05
IS7310A (is) 2004-06-14
EP1467731A1 (en) 2004-10-20
CA2472238A1 (en) 2003-07-31
WO2003061652A8 (en) 2004-09-10
UY27615A1 (es) 2003-08-29
TNSN04121A1 (en) 2006-06-01
CN1620291A (zh) 2005-05-25
PL371487A1 (en) 2005-06-13
TW200302094A (en) 2003-08-01
HRP20040659A2 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
CN108884068B (zh) 作为dub抑制剂的1-氰基-吡咯烷衍生物
JP6633618B2 (ja) 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体
CA2419633C (en) Substituted imidazoles as tafia inhibitors
WO2003013526A1 (en) Anticoagulant compounds
CN101163675A (zh) 含氮杂环化合物
US6759426B2 (en) 3-(Imidazolyl)-2-aminopropanoic acids
WO2000006564A1 (fr) Composes de maleimide disubstitues et utilisation en medecine de ces derniers
OA12756A (en) 3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors.
KR20190100232A (ko) 인테그린 길항제
US6713496B2 (en) 3-(imidazolyl)-2-alkoxypropanoic acids
PT1575942E (pt) Compostos possuindo efeito de inibição selectivo sobre a gsk3
US6949577B2 (en) Pharmaceuticals
AU2003237012A1 (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
US20020147229A1 (en) Pharmaceuticals
WO2019144811A1 (zh) 四氢异喹啉类衍生物及其制备方法和用途
US20070099927A1 (en) Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors
JP2006527731A (ja) Ｘａ因子阻害剤としてのピロリジン−２−オン
JP2006527729A (ja) 急性血管疾患の治療用のｘａ因子阻害剤としての１−フェニル−２−オキソ−３−スルホニルアミノ−ピロリジン誘導体および関連化合物
WO2006045459A1 (en) Thrombin inhibitors
JP2006527728A (ja) Ｘａ因子の阻害剤としての２−ピロリドン誘導体およびその使用
ZA200301230B (en) Substituted imidazoles as tafia inhibitors.